The phase II trial didn’t look at MACE, but excitement over inflammation’s role in CVD—and how to tame it—isn’t done yet.

The lack of impact on outcomes was surprising, says the investigator, though the FAST-CTCA trial may still come through.

While no comparable guidelines exist in the US, Richard Kovacs of the ACC said he considers it to be “eye-opening.” ...

Without reducing death or major bleeding, Toby Rogers says the results can be interpreted based on one’s ‘starting ...

This month, readers gravitated most toward the memory of David Taggart. Stories interpreting data from ESC 2026 also drew ...

Larger trials with longer follow-up are still needed to cement CSP as an alternative to biventricular pacing, experts say.

Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten ...

SWITCH-SWEDEHEART’s unique design randomized healthcare regions but wasn’t a head-to-head comparison with ticagrelor.

An intervention in rural China continued to impact hypertension, CV events, and dementia risk 4 years after it ended.

As the first trial of these valve interventions to impact HF hospitalization and mortality, it “feels like a COAPT-like ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

September 2, 2026 | Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation. Receive the the latest news, research, and ...